BG105470A - Химиотерапия на рак с ацетилдиналин в комбинация с гемцитабин, капецитабин или цисплатина - Google Patents

Химиотерапия на рак с ацетилдиналин в комбинация с гемцитабин, капецитабин или цисплатина

Info

Publication number
BG105470A
BG105470A BG105470A BG10547001A BG105470A BG 105470 A BG105470 A BG 105470A BG 105470 A BG105470 A BG 105470A BG 10547001 A BG10547001 A BG 10547001A BG 105470 A BG105470 A BG 105470A
Authority
BG
Bulgaria
Prior art keywords
treament
tumours
acetyldinaline
capecitabine
gemcitabine
Prior art date
Application number
BG105470A
Other languages
English (en)
Inventor
William GROVE
Wayne KLOHS
Ronald MERRIMAN
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of BG105470A publication Critical patent/BG105470A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретението се отнася до комбинация на ацетилдиналин с гемцитабин, негова фармацевтично приемливасол, капцитабин или цисплатина за лечение на рак.
BG105470A 1998-09-25 2001-04-25 Химиотерапия на рак с ацетилдиналин в комбинация с гемцитабин, капецитабин или цисплатина BG105470A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10180998P 1998-09-25 1998-09-25
PCT/US1999/015386 WO2000018393A1 (en) 1998-09-25 1999-07-08 Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin

Publications (1)

Publication Number Publication Date
BG105470A true BG105470A (bg) 2001-12-29

Family

ID=22286531

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105470A BG105470A (bg) 1998-09-25 2001-04-25 Химиотерапия на рак с ацетилдиналин в комбинация с гемцитабин, капецитабин или цисплатина

Country Status (34)

Country Link
US (3) US6469058B1 (bg)
EP (1) EP1115391B1 (bg)
JP (1) JP2002525320A (bg)
KR (1) KR20010075348A (bg)
CN (1) CN1319009A (bg)
AP (1) AP2001002109A0 (bg)
AT (1) ATE225655T1 (bg)
AU (1) AU762079B2 (bg)
BG (1) BG105470A (bg)
BR (1) BR9913952A (bg)
CA (1) CA2342981A1 (bg)
CZ (1) CZ2001905A3 (bg)
DE (1) DE69903458T2 (bg)
DK (1) DK1115391T3 (bg)
EA (1) EA200100369A1 (bg)
EE (1) EE200100187A (bg)
ES (1) ES2185378T3 (bg)
GE (1) GEP20043199B (bg)
HK (1) HK1040190A1 (bg)
HR (1) HRP20010225B1 (bg)
HU (1) HUP0103640A3 (bg)
ID (1) ID30046A (bg)
IL (1) IL141951A0 (bg)
IS (1) IS5888A (bg)
NO (1) NO20011493L (bg)
NZ (1) NZ510504A (bg)
OA (1) OA11659A (bg)
PL (1) PL348673A1 (bg)
PT (1) PT1115391E (bg)
SK (1) SK3602001A3 (bg)
TR (1) TR200100859T2 (bg)
WO (1) WO2000018393A1 (bg)
YU (1) YU22401A (bg)
ZA (1) ZA200102233B (bg)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2001002109A0 (en) * 1998-09-25 2001-03-31 Warner Lambert Co Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin.
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
US20080075762A1 (en) * 2001-10-03 2008-03-27 Paul Tardi Compositions for delivery of drug combinations
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
NZ567758A (en) * 2002-03-04 2009-07-31 Merck Hdac Res Llc Methods of inducing terminal differentiation using suberoylanilide hydrozmic acid (SAHA)
US7456219B2 (en) * 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
EP1501489A4 (en) * 2002-04-15 2007-11-21 Sloan Kettering Inst Cancer COMBINATION THERAPY FOR THE TREATMENT OF CANCER
US20070032422A1 (en) 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers
US8026216B2 (en) 2002-10-24 2011-09-27 Spectrum Pharmaceuticals, Inc. Methods and compositions for contributing to the treatment of cancers
GB0226434D0 (en) * 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
EP1562601A1 (en) * 2002-11-15 2005-08-17 Warner-Lambert Company LLC Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer
US20060165744A1 (en) * 2003-05-22 2006-07-27 Neopharm, Inc Combination liposomal formulations
PE20050206A1 (es) * 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
CN100431606C (zh) * 2004-11-22 2008-11-12 山东蓝金生物工程有限公司 一种抗癌药物组合物
US7957507B2 (en) 2005-02-28 2011-06-07 Cadman Patrick F Method and apparatus for modulating a radiation beam
CN100443081C (zh) * 2005-04-05 2008-12-17 吴一心 木犀草素与一种铂类化疗药物联合用于制备抗肿瘤的药物
US8232535B2 (en) 2005-05-10 2012-07-31 Tomotherapy Incorporated System and method of treating a patient with radiation therapy
KR20080039919A (ko) 2005-07-22 2008-05-07 토모테라피 인코포레이티드 방사선 치료를 받는 환자의 호흡 상태를 검출하는 시스템및 방법
JP2009502253A (ja) 2005-07-22 2009-01-29 トモセラピー・インコーポレーテッド 関心の移動領域に対して放射線療法を施すシステムおよび方法
WO2007014108A2 (en) * 2005-07-22 2007-02-01 Tomotherapy Incorporated Method and system for evaluating quality assurance criteria in delivery of a treament plan
JP2009502251A (ja) 2005-07-22 2009-01-29 トモセラピー・インコーポレーテッド 放射線治療システムによって送達された線量を評価するシステム及び方法
US7643661B2 (en) * 2005-07-22 2010-01-05 Tomo Therapy Incorporated Method and system for evaluating delivered dose
US8442287B2 (en) 2005-07-22 2013-05-14 Tomotherapy Incorporated Method and system for evaluating quality assurance criteria in delivery of a treatment plan
JP5390855B2 (ja) 2005-07-23 2014-01-15 トモセラピー・インコーポレーテッド ガントリおよび治療台の協調した動きを利用した放射線療法の撮像およびデリバリー
CN101534852B (zh) * 2006-08-31 2013-02-13 光谱医药公司 通过施用内皮素激动剂使得肿瘤细胞对放疗敏化
AU2009208481B2 (en) * 2008-01-28 2014-05-29 Nanocarrier Co., Ltd. Pharmaceutical composition and combined agent
FR2937867B1 (fr) * 2008-11-03 2011-03-04 Biorebus Association pharmaceutique contenant l acide lipoique et l acide hydroxycitrique a titre de principes actifs.
JP5687687B2 (ja) 2009-04-06 2015-03-18 大塚製薬株式会社 癌を治療するための（２’−デオキシ−リボフラノシル）−１，３，４，７−テトラヒドロ−（１，３）ジアゼピン−２−オン誘導体
WO2012003413A1 (en) * 2010-06-30 2012-01-05 The Broad Institute, Inc. Novel solid forms of tacedinaline
US8691875B2 (en) 2011-07-01 2014-04-08 Broad Institute, Inc. Solid forms of tacedinaline
US9308235B2 (en) 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
EP2711008A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer
EP2711007A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer
EP2711009A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. Compounds for use in treating or preventing primary and metastatic breast and prostate cancer
CN105027227B (zh) 2013-02-26 2017-09-08 安科锐公司 电磁致动的多叶准直器
US10189797B2 (en) 2015-12-30 2019-01-29 Duke University Chemical modulators of immune checkpoints and therapeutic use
US11987579B2 (en) 2018-07-30 2024-05-21 Duke University Niclosamide analogues and therapeutic use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5562925A (en) * 1970-04-20 1996-10-08 Research Corporation Tech. Inc. Anti-tumor method
NZ219974A (en) * 1986-04-22 1989-08-29 Goedecke Ag N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
AU6878198A (en) * 1997-04-24 1998-11-13 Warner-Lambert Company Use of acetyldinaline for the manufacture of a medicament for the treatment of renal cell carcinoma
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
AP2001002109A0 (en) * 1998-09-25 2001-03-31 Warner Lambert Co Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin.

Also Published As

Publication number Publication date
GEP20043199B (en) 2004-03-25
PL348673A1 (en) 2002-06-03
HK1040190A1 (zh) 2002-05-31
CA2342981A1 (en) 2000-04-06
OA11659A (en) 2004-12-08
DE69903458T2 (de) 2003-07-10
BR9913952A (pt) 2001-06-12
NO20011493D0 (no) 2001-03-23
EP1115391A1 (en) 2001-07-18
IS5888A (is) 2001-03-14
EA200100369A1 (ru) 2001-10-22
HRP20010225B1 (en) 2004-10-31
NO20011493L (no) 2001-05-23
AP2001002109A0 (en) 2001-03-31
PT1115391E (pt) 2003-02-28
ZA200102233B (en) 2002-06-18
DE69903458D1 (de) 2002-11-14
AU5092199A (en) 2000-04-17
EE200100187A (et) 2002-08-15
DK1115391T3 (da) 2003-02-10
US20030086965A1 (en) 2003-05-08
HRP20010225A2 (en) 2002-04-30
ATE225655T1 (de) 2002-10-15
NZ510504A (en) 2003-09-26
US6469058B1 (en) 2002-10-22
ES2185378T3 (es) 2003-04-16
CN1319009A (zh) 2001-10-24
JP2002525320A (ja) 2002-08-13
HUP0103640A2 (en) 2002-06-29
AU762079B2 (en) 2003-06-19
WO2000018393A1 (en) 2000-04-06
HUP0103640A3 (en) 2003-01-28
IL141951A0 (en) 2002-03-10
ID30046A (id) 2001-11-01
KR20010075348A (ko) 2001-08-09
YU22401A (sh) 2004-03-12
US20030170300A1 (en) 2003-09-11
SK3602001A3 (en) 2002-07-02
EP1115391B1 (en) 2002-10-09
TR200100859T2 (tr) 2001-08-21
CZ2001905A3 (cs) 2001-08-15

Similar Documents

Publication Publication Date Title
BG105470A (bg) Химиотерапия на рак с ацетилдиналин в комбинация с гемцитабин, капецитабин или цисплатина
IL100942A0 (en) 2,4-diaminoquinazoline derivatives for enhancing antitumor activity
MXPA01004648A (es) Tratamientro de enfermedades hematologicas malignas asociadas con celulas tumorales de la circulacion usando el anticuerpo quimerico anti-cd20.
AU2592600A (en) Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
HU9301314D0 (en) Quinazoline derivatves for improving anto-tumouric activity
BG102999A (bg) Нови 2,3 дизаместени-4(3н)-хиназолинони
GB9818916D0 (en) Use
SG144712A1 (en) Nordihydroguaiartic derivaties for use in treatment of tumors
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
PL330496A1 (en) Methods of and compositions for treating and preventing tumours, disorders associated with tumours as well as cachexy
EP1019057A4 (en) METHOD FOR THE PREVENTION AND TREATMENT OF ESTROGEN-INDUCED DISEASES AND DISORDERS
MY137303A (en) Methods for treating proliferative diseases
NZ512210A (en) Camptothecin analogs useful for treating cancer and leukemia
DE3685484D1 (bg)
HU9701060D0 (en) Pharmaceutical composition for treating cognitive disturbs
IL131478A0 (en) Methods for treatment of scar tissue
MXPA04005207A (es) Metodos para tratar cancer utilizando un inhibidor de la farnesil proteina transferasa y agentes antineoplasticos.
EP0938900A4 (en) MEANS OF PREVENTION OR HEALING OF STOMATITIS
IL145149A0 (en) Radioactive cisplatin in the treatment of cancer
ZA200101188B (en) DNAzymes and methods for treating restenosis.
EP1083914A4 (en) TREATING ARTHRITIS AND OTHER SIMILAR DISORDERS
IL133141A0 (en) Composition comprising ketanserin and l-carnitine or an alkanoyl l-carnitine for the treatment of crps
DE59505934D1 (de) Vitamin b 12-haltige sanddornkonzentrate oder -extrakte
MXPA05002477A (es) Asialo-interferones y el tratamiento de cancer de higado.
RU96107442A (ru) Способ лечения вегетативной дистонии с парасимпатическими пароксизмами